Search

Your search keyword '"Cyclin-Dependent Kinase 2"' showing total 15,627 results

Search Constraints

Start Over You searched for: Descriptor "Cyclin-Dependent Kinase 2" Remove constraint Descriptor: "Cyclin-Dependent Kinase 2"
15,627 results on '"Cyclin-Dependent Kinase 2"'

Search Results

1. Melanoma progression and prognostic models drawn from single-cell, spatial maps of benign and malignant tumors.

2. Recent Development of CDK2 Inhibitors as Anticancer Drugs: An Update (2015–2023)

3. Biolayer Interferometry Assay for Cyclin-Dependent Kinase-Cyclin Association Reveals Diverse Effects of Cdk2 Inhibitors on Cyclin Binding Kinetics

4. Cyclin-dependent kinase-mediated phosphorylation and the negative regulatory domain of transcription factor B-Myb modulate its DNA binding

5. Binding selectivity-dependent molecular mechanism of inhibitors towards CDK2 and CDK6 investigated by multiple short molecular dynamics and free energy landscapes

6. Binding selectivity-dependent molecular mechanism of inhibitors towards CDK2 and CDK6 investigated by multiple short molecular dynamics and free energy landscapes.

7. S‐adenosylmethionine inhibits la ribonucleoprotein domain family member 1 in murine liver and human liver cancer cells

8. Design, synthesis, and biological evaluation of furan‐bearing pyrazolo[3,4‐b]pyridines as novel inhibitors of CDK2 and P53–MDM2 protein–protein interaction.

9. 2.5 Å-resolution structure of human CDK-activating kinase bound to the clinical inhibitor ICEC0942

10. Tranilast induces MiR-200c expression through blockade of RelA/p65 activity in leiomyoma smooth muscle cells

11. Proline-rich protein PRR19 functions with cyclin-like CNTD1 to promote meiotic crossing over in mouse

12. Repurposed benzydamine targeting CDK2 suppresses the growth of esophageal squamous cell carcinoma.

13. CRIF1 as a potential target to improve the radiosensitivity of osteosarcoma.

14. CRIF1 as a potential target to improve the radiosensitivity of osteosarcoma

15. Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes.

16. Structural basis for the ORC1‐Cyclin A association

17. CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs

18. Inhibition of Cyclin-dependent Kinase 2 Signaling Prevents Liver Ischemia and Reperfusion Injury

19. Comparative binding affinity analysis of dual CDK2/FLT3 inhibitors.

20. Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies

21. EMI1 switches from being a substrate to an inhibitor of APC/CCDH1 to start the cell cycle

22. High-Throughput Kinetic Analysis for Target-Directed Covalent Ligand Discovery.

23. Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma

24. LaCl3⋅7H2O as an Effective Catalyst for the Synthesis of α-Aminophosphonates under Solvent-Free Conditions and Docking Simulation of Ligand Bond Complexes of Cyclin-Dependent Kinase 2.

25. Hsa_circ_0000520 overexpression increases CDK2 expression via miR-1296 to facilitate cervical cancer cell proliferation

26. FBW7 Loss Promotes Chromosomal Instability and Tumorigenesis via Cyclin E1/CDK2–Mediated Phosphorylation of CENP-A

27. Structural basis of divergent cyclin‐dependent kinase activation by Spy1/RINGO proteins

28. Multi‐kinase framework promotes proliferation and invasion of lung adenocarcinoma through activation of dynamin‐related protein 1

29. Cyclin E as a potential therapeutic target in high grade serous ovarian cancer.

30. αCP binding to a cytosine-rich subset of polypyrimidine tracts drives a novel pathway of cassette exon splicing in the mammalian transcriptome

31. Long non-coding RNA LINC00630 facilitates hepatocellular carcinoma progression through recruiting transcription factor E2F1 to up-regulate cyclin-dependent kinase 2 expression.

32. Efficient CRISPR-rAAV engineering of endogenous genes to study protein function by allele-specific RNAi

33. Reinforcing targeted therapeutics with phenotypic stability factors

34. Findings in Cancer Reported from Bharti Vidyapeeth Deemed University Medical College (Identification of Potential Phytochemicals Against Cyclin-dependent Kinase 1 and Cyclin-dependent Kinase 2: a Molecular Docking and Molecular Dynamic Approach).

35. Hsa_circ_0000520 overexpression increases CDK2 expression via miR-1296 to facilitate cervical cancer cell proliferation.

36. Regulation of Hepatitis B Virus Replication by Cyclin Docking Motifs in Core Protein.

37. Discovery of novel macrocyclic derivatives as potent and selective cyclin-dependent kinase 2 inhibitors.

38. Protein structural ensembles are revealed by redefining X-ray electron density noise

39. A structure-guided approach for protein pocket modeling and affinity prediction.

40. Microhomology-mediated End Joining and Homologous Recombination share the initial end resection step to repair DNA double-strand breaks in mammalian cells

41. A Cdk7-Cdk4 T-Loop Phosphorylation Cascade Promotes G1 Progression

42. Multi‐kinase framework promotes proliferation and invasion of lung adenocarcinoma through activation of dynamin‐related protein 1.

43. A CONVENIENT SYNTHESIS OF NOVEL PYRAZOLO[3,4-D] PYRIMIDINE AND PYRAZOLO[4,3-E][1,2,4]TRIAZOLO[1,5-C] PYRIMIDINE DERIVATIVES TARGETING CDK2.

44. Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions.

45. Inhibited histone deacetylase 3 ameliorates myocardial ischemia–reperfusion injury in a rat model by elevating microRNA‐19a‐3p and reducing cyclin‐dependent kinase 2.

46. Downregulation of Cdc6 and pre-replication complexes in response to methionine stress in breast cancer cells

47. Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma

48. Study Results from University of Nottingham Provide New Insights into Ductal Carcinoma [Clinicopathological Significance of Cyclin-Dependent Kinase 2 (CDK2) in Ductal Carcinoma In Situ and Early-Stage Invasive Breast Cancers].

49. Structure of cyclin‐dependent kinase 2 (CDK2) in complex with the specific and potent inhibitor CVT‐313.

50. Optimization of norbornyl‐based carbocyclic nucleoside analogs as cyclin‐dependent kinase 2 inhibitors.

Catalog

Books, media, physical & digital resources